Opinion

Video

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Related Videos
Image credit: Ophthalmology Times; Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.